Why Netflix Stock Lost 13% in July
Netflix declined steadily over the month due to valuation-related fears.
The company delivered a strong second-quarter earnings report, but it wasn't enough to lift the stock.
The stock still looks like a buy over the long term.
10 stocks we like better than Netflix ›
Netflix (NASDAQ: NFLX) has been one of the top-performing stocks in the market over the last few years, but that blistering growth seemed to catch up with it in July, as a strong second-quarter earnings report wasn't enough to push the stock higher.
Instead, investors bailed on the stock as valuation concerns seemed to override another round of solid growth. According to data from S&P Global Market Intelligence, the streaming stock finished the month down 13%.
As you can see from the chart, the stock headed lower over much of July, even as the S&P 500 (SNPINDEX: ^GSPC) finished with a 2.2% gain.
NFLX data by YCharts
Netflix takes a step back
Netflix's pullback last month showcases what happens when a stock is priced to perfection. The stock was already falling heading into the second-quarter report, even though there was no major news out on the company.
When it came time for its update, Netflix delivered strong numbers. Revenue rose 16% to $11.08 billion, narrowly topping expectations at $11.04 billion.
Netflix no longer reports quarterly subscriber growth, but its growth was broad-based across all four of its regions, with currency-neutral revenue growth of 15% or better in each territory. On the bottom line, its operating margin jumped from 27.2% in the quarter a year ago to 34.1%, and it reported earnings per share of $7.19, up from $4.88 in the quarter a year ago and better than the consensus at $7.06.
The company also raised its guidance for the year, upping its revenue forecast from $43.5 billion-$44.5 billion to $44.8 billion-$45.8 billion and its operating margin from 29% to 29.5%. However, that was not enough to push the stock higher, as pressure from valuation and high expectations leading into the report seemed to have overcome the "beat and raise" results.
Is Netflix a buy after the pullback?
Netflix is now trading at a price-to-earnings ratio of 50, which is expensive, even for a growth stock.
However, its recent push into advertising is paying off, and its local content strategy is driving growth around the world. Its subscription model should also drive profit margins higher as its subscriber base continues to grow.
In the near future, valuation pressure could push the stock lower, but over the longer term, its leadership in streaming and broader growth tailwinds should make the stock a winner.
Should you invest $1,000 in Netflix right now?
Before you buy stock in Netflix, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Netflix wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!*
Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 4, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
SBAC Earnings Jump on Strong Sales
Key Points Revenue (GAAP) reached $698.98 million, surpassing the analyst estimate by 4.1% (GAAP), driven by robust domestic leasing and higher site development activity. Adjusted Funds From Operations (AFFO) per share was $3.17 (non-GAAP), though down 3.6% year over year due to higher interest expenses. Full-year 2025 guidance for revenue, AFFO (non-GAAP), and Adjusted EBITDA (non-GAAP) was raised on strong backlogs and the early Millicom site acquisition closing. These 10 stocks could mint the next wave of millionaires › SBA Communications (NASDAQ:SBAC), a leading owner and operator of wireless communications towers, announced results for the second quarter on August 4, 2025. GAAP revenue was $698.98 million, above the expected $671.15 million (GAAP) and up 5.8% year over year. Diluted earnings per share (GAAP) were $2.09, above the $2.13 consensus (Non-GAAP) EPS estimate, but net income jumped 41.5% year over year. Adjusted Funds From Operations (AFFO) per share came in at $3.17, though declining from the prior year. Management raised financial guidance for full year 2025 across all key metrics, reflecting strong domestic demand, accelerated site acquisitions, and favorable leasing trends. The quarter showed solid progress in several business lines, despite margin pressures and increased interest costs. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS – Diluted (GAAP) $2.09 $2.13 $1.51 38.5 % Revenue $698.98 million $671.15 million $660.48 million 5.8% Adjusted EBITDA $475.5 million $467.1 million 1.8% AFFO per Share $3.17 $3.29 (3.6 %) Tower Cash Flow $511.2 million $503.9 million 1.4 % Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Understanding SBA Communications and Its Business Model SBA Communications owns, operates, and leases wireless tower infrastructure to mobile carriers and other wireless service providers. Its primary business is renting antenna space on its towers, a model that delivers stable, recurring revenue. Site leasing generates most of its operating profit, while the company also provides site development services, such as construction and network upgrades, to wireless carriers. In recent years, SBA Communications has focused on three major areas: expanding its international tower footprint, maximizing tower capacity by increasing colocation (multiple tenants per tower), and securing long-term control of the land under its towers. The company also closely follows wireless technology trends, like the rollout of 5G networks, as these drive demand for more tower space and additional equipment installations. Quarter Highlights: Growth Drivers and Strategic Moves In Q2 2025, site leasing remained the core of SBA Communications' business, accounting for 97.4% of segment operating profit. Domestic site leasing revenue grew to $469.8 million, up 1.4% from a year ago. International site leasing revenue was $162.0 million, a slight decrease on a reported (GAAP) basis, but up 4.0% when adjusting for foreign currency movements. The tower cash flow margin, a key indicator of profitability for tower operations, held steady at 81.0% (non-GAAP). The services segment, which includes site development, saw rapid growth as revenue nearly doubled to $67.2 million. This surge reflects increased carrier investment in network upgrades and new infrastructure. However, these projects have lower margins compared with core site leasing -- the spike in services revenue contributed to an overall decline in company-wide Adjusted EBITDA margin compared to Q2 2024. The company accelerated the integration of more than 4,300 newly acquired sites from the Millicom deal several months ahead of schedule. This brought the total tower count up to 44,065 as of June 30, 2025. It also advanced plans to sell its Canadian tower assets, entering into an agreement on July 21, 2025 to sell all 369 towers and related operations in Canada, with the transaction expected to close in Q4 2025, expecting this divestiture to be immediately beneficial to AFFO per share after closing, as stated by management in the earnings release. These actions demonstrate a strategy of growing internationally while exiting less efficient markets to focus on higher-return regions. Capital allocation remained active, with 799,000 shares repurchased and $1.45 billion authorized for future buybacks. Quarterly dividends held steady at $1.11 per share. The company maintained a high level of debt, with a net debt to adjusted EBITDA ratio of 6.5x, and net cash interest expense rose 23.2% year over year from Q2 2024 to $111.5 million. Management emphasized that the balance sheet remains strong. Strategic Business Areas and Their Impact Site leasing continues to dominate company profits, supported by the recurring nature of tower rental agreements with wireless carriers. This stability is underpinned by long-term contracts. SBA Communications closely monitors lease churn and seeks to add new tenants through strategic marketing and infrastructure upgrades. International expansion is a core strategy. While most new towers come from acquisition -- as with the Millicom deal -- the company also constructs new sites in regions where wireless networks are maturing. Diversifying across 13 countries insulates SBA Communications from market-specific risks and taps into growing demand for wireless infrastructure in developing regions. Maximizing tower capacity is another focus. By increasing the average number of tenants per tower, SBA Communications boosts revenue from existing assets with limited additional cost. About 75% of new U.S. leasing activity in Q1 2025 derived from colocations, which generate higher incremental revenue than simple contract amendments. Often prompted by requirements to meet 5G coverage mandates. The company also invests in long-term land control through ownership and long-term leases. This provides operational security, cost predictability, and margin protection well into the future. About 72% of tower sites are on land with over 20 years of control remaining as of December 31, 2024, and the company reported ongoing spending to extend lease terms where possible. Looking Ahead: Guidance and Market Trends Management raised its full-year 2025 financial outlook, expecting total revenue (GAAP) to reach $2.78–2.83 billion, AFFO per share (non-GAAP) of $12.65–13.02, and adjusted EBITDA of $1.91–1.93 billion. These increases reflect strong current leasing backlogs, robust site development, early benefits from the Millicom site acquisition, and positive foreign currency effects. The Canadian asset sale, which is still pending, is not yet included in the outlook. But overall commentary remains constructive for continued growth in the U.S. Key risks highlighted this period include margin pressures, flat-to-slow international organic growth due to carrier churn in markets like Brazil, and persistently high debt levels that heighten interest expenses. Nonetheless, strong domestic leasing demand, expanding service backlogs, and high levels of tower colocation suggest ongoing near-term growth. SBA Communications does pay a dividend, and the current quarterly dividend remains at $1.11 per share. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
an hour ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
3 hours ago
- Globe and Mail
AGL Investors Have Opportunity to Join agilon health, inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President and CEO Steven Sell was stepping down immediately. The Company also withdrew its full-year 2025 financial guidance. Based on this news, shares of Agilon fell by more than 27.2% in after hours trading on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
